It doesn’t matter what country you are in, regulators always seem to be reworking rules to make their markets better. The problem is that, often, different market objectives (and their solutions) ...

Structure Therapeutics recently reported strong Phase 2b results for its oral weight-loss candidate aleniglipron, secured a ...

I maintain a Hold rating on Structure Therapeutics due to competitive pressures and lingering doubts about aleniglipron’s efficacy and data integrity. Aleniglipron’s tolerability could be a ...

Cantor Fitzgerald maintains its bullish views on Structure Therapeutics. Cantor analyst says stock significantly undervaluing GPCR's attractive pipeline of obesity candidates. Live on Wednesday June ...